Roche’s anti-TIGIT drug suffers a phase III cancer setback
Asher Mullard
Topics & Concepts
TIGITSetbackDrugCancer drugsMedicinePharmacologyCancerInternal medicineImmunotherapyEngineeringCivil engineeringProtein Degradation and InhibitorsClick Chemistry and ApplicationsCancer therapeutics and mechanisms